Elicio Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Moti Investments LLC has reported beneficial ownership of 1,408,892 shares, representing 6.1% of the outstanding common stock of Elicio Therapeutics, Inc.
NASDAQ
Knoll Capital Management, LLC, along with Fred Knoll and Gakasa Holdings, LLC, has reported beneficial ownership of 1,211,957 shares, representing 5.3% of Elicio Therapeutics, Inc.'s common stock.
NASDAQ
Actyus Private Equity SGIIC, S.A. has filed an amended Schedule 13G, disclosing a 1.64% beneficial ownership stake in Elicio Therapeutics, Inc.
NASDAQ
Actyus Private Equity SGIIC, S.A. has filed an amended Schedule 13G, reporting a 5.35% beneficial ownership stake in Elicio Therapeutics, Inc. as of March 31, 2025.
NASDAQ
Knoll Capital Management, Fred Knoll, and Gakasa Holdings, LLC have jointly disclosed a beneficial ownership of 5.2% in Elicio Therapeutics, Inc.'s common stock.
NASDAQ
Actyus Private Equity SGIIC, S.A. has reported a 5.45% beneficial ownership stake in Elicio Therapeutics, Inc., holding 587,818 shares of common stock.